Morgan Stanley Reiterates Equalweight Rating on Biogen (BIIB)
March 30, 2026 9:25 AM
Morgan Stanley analyst Terence Flynn reiterated an Equalweight rating and $190.00 price target on Biogen (NASDAQ: BIIB)The analyst comments "Investigators ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
